HRTX Q2 2024 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+13.4% YoY

Gross Profit

$26M70.8% margin

Operating Income

-$6M-17.9% margin

Net Income

-$9M-25.6% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+3.9%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$218M

Total Liabilities

$256M

Stockholders' Equity

-$38M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$32M	+13.4%
Gross Profit	$26M	$12M	+119.8%
Operating Income	-$6M	-$42M	+84.8%
Net Income	-$9M	-$42M	+78.0%

Revenue Segments

C I N V A N T I

$25M71%

Z Y N R E L E F

$6M17%

S U S T O L

$4M12%